STOCK TITAN

[Form 4] Hims & Hers Health, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Patrick Harrison Carroll, Chief Medical Officer and director of Hims & Hers Health, Inc. (HIMS), reported transactions dated 09/15/2025 on Form 4. He was granted 16,521 RSUs that convert one-for-one into Class A common stock and additional RSU awards listed in the filing totaling 16,521 + 8,148 + 4,840 + 3,533 units across entries. The issuer withheld 6,500 shares to satisfy tax withholding at a reported price of $53.96, reducing reported Class A common stock beneficial ownership from 186,461 to 179,961 following the withholding. The RSUs are subject to service-based vesting schedules, generally over four years with quarterly vesting dates specified in the filing.

The filing is a reporting of equity awards and related withholding; it documents grant mechanics, vesting schedules, and post-transaction beneficial ownership levels but does not provide compensation totals in dollars beyond the withholding price or other company financial metrics.

Patrick Harrison Carroll, Direttore Medico e amministratore di Hims & Hers Health, Inc. (HIMS), ha riportato operazioni datate 09/15/2025 sul Modulo 4. A lui sono stati conferiti 16.521 RSU che si trasformano one-for-one in azioni ordinarie di Classe A e ulteriori premi RSU elencati nel fascicolo per un totale di 16.521 + 8.148 + 4.840 + 3.533 unità tra le voci. L’emittente ha trattenuto 6.500 azioni per soddisfare la ritenuta fiscale a un prezzo riportato di 53,96 USD, riducendo la proprietà economica dichiarata di azioni ordinarie di Classe A da 186.461 a 179.961 dopo la trattenuta. Le RSU sono soggette a piani di vesting basati sul servizio, generalmente su quattro anni con date di vesting trimestrali indicate nel fascicolo.

Il fascicolo è una rendicontazione di premi azionari e ritenute correlate; documenta le meccaniche di concessione, i calendari di vesting e i livelli di proprietà economica post-trasazione, ma non fornisce totali di compenso in dollari oltre al prezzo di ritenuta o ad altri indicatori finanziari dell’azienda.

Patrick Harrison Carroll, Director Médico y director de Hims & Hers Health, Inc. (HIMS), reportó transacciones con fecha 15/09/2025 en el Formulario 4. Le otorgaron 16.521 RSU que se convierten uno a uno en acciones ordinarias Clase A y premios RSU adicionales listados en el expediente que suman un total de 16.521 + 8.148 + 4.840 + 3.533 unidades entre las entradas. El emisor retuvo 6.500 acciones para cumplir con la retención fiscal a un precio reportado de $53.96, reduciendo la propiedad beneficiaria reportada de acciones ordinarias Clase A de 186.461 a 179.961 tras la retención. Las RSU están sujetas a planes de vesting basados en el servicio, generalmente a lo largo de cuatro años con fechas de vesting trimestrales indicadas en el expediente.

El expediente es un informe de premios de acciones y retenciones relacionadas; documenta la mecánica de concesión, calendarios de vesting y niveles de propiedad beneficiosa post-trasacción, pero no proporciona totales de compensación en dólares más allá del precio de retención ni otros indicadores financieros de la empresa.

Patrick Harrison Carroll, Hims & Hers Health, Inc. (HIMS)의 최고의료책임자 겸 이사는 2025-09-15자로 Form 4에 거래를 보고했습니다. 그에게는 16,521 RSU가 부여되어 1대1로 Class A 보통주로 전환되며, 파일에 기재된 추가 RSU 보상도 합계 16,521 + 8,148 + 4,840 + 3,533 단위로 항목에 기재되어 있습니다. 발행사는 세금 원천징수를 충당하기 위해 6,500주를 보유했고, 보고된 가격 $53.96로 원천징수를 실시하여, 원천징수 후 Class A 보통주 유익소유가 186,461주에서 179,961주로 감소했습니다. RSU는 서비스 기반의 vesting 일정에 따라 일반적으로 4년 동안 분기별 vesting 날짜가 파일에 명시되어 있습니다.

이 제출물은 주식 보상 및 관련 원천징수에 대한 보고로, 부여 메커니즘, vesting 일정 및 거래 후 유익소유 수준을 문서화하지만, 원천징수 가격이나 회사의 다른 재무 지표를 넘어서는 보상 총액은 제공하지 않습니다.

Patrick Harrison Carroll, Directeur médical et administrateur de Hims & Hers Health, Inc. (HIMS), a signalé des transactions datées du 15/09/2025 sur le Formulaire 4. Il a reçu 16 521 RSU qui se convertissent en une action ordinaire de Classe A au même rapport et des suppléments RSU supplémentaires listés dans le dossier totalisant 16 521 + 8 148 + 4 840 + 3 533 unités. L’émetteur a retenu 6 500 actions pour satisfaire la retenue fiscale à un prix affiché de 53,96 USD, réduisant la propriété bénéficiaire déclarée d’actions ordinaires de Classe A de 186 461 à 179 961 après retenue. Les RSU sont soumises à des plans d’acquisition fondés sur le service, généralement sur quatre ans avec des dates d’acquisition trimestrielles indiquées dans le dossier.

Le dossier est un rapport sur les attributions d’actions et les retenues associées; il décrit les mécanismes d’attribution, les calendriers d’acquisition et les niveaux de propriété bénéficiaire post-transaction, mais ne fournit pas les totaux de rémunération en dollars au-delà du prix de retenue ni d’autres indicateurs financiers de l’entreprise.

Patrick Harrison Carroll, Chief Medical Officer und Direktor von Hims & Hers Health, Inc. (HIMS), berichtete Transaktionen vom 15.09.2025 im Formular 4. Ihm wurden 16.521 RSU gewährt, die eins-zu-eins in Class A Stammaktien umgewandelt werden, sowie zusätzliche RSU-Boni, die in der Einreichung aufgeführt sind und insgesamt 16.521 + 8.148 + 4.840 + 3.533 Einheiten ergeben. Der Emittent hielt 6.500 Aktien ein, um die Steuerabzüge zu decken, zu einem angegebenen Preis von 53,96 USD, wodurch die berichtete Beneficial Ownership der Class A Stammaktien nach dem Abzug von 186.461 auf 179.961 sinkt. Die RSUs unterliegen dienstbasierenden Vesting-Plänen, in der Regel über vier Jahre mit vierteljährlichen Vesting-Daten, die in der Einreichung angegeben sind.

Die Einreichung dokumentiert Equity Awards und damit verbundene Abzüge; sie beschreibt Vergabe-Mechanismen, Vesting-Zeitpläne und Post-Transaktions-Beneficial Ownership-Level, liefert jedoch keine Vergütungsbeträge in Dollar über den Abzugspreis oder andere Finanzkennzahlen des Unternehmens.

Patrick Harrison Carroll، المدير الطبي ورئيس مجلس إدارة شركة Hims & Hers Health, Inc. (HIMS)، أبلغ عن معاملات مؤرخة في 15/09/2025 في النموذج 4. لقد مُنح 16,521 RSU تتحول واحدًا إلى واحد إلى أسهم عادية من الفئة A ونجوم RSU إضافية مدرجة في الملف بإجمالي 16,521 + 8,148 + 4,840 + 3,533 وحدة عبر الإدخالات. حافَظ المُصدر على 6,500 سهم لتلبية الحجز الضريبي بسعر مُبلغ عنه قدره $53.96، مما قلّل الملكية المستفيدة من الأسهم العادية من الفئة A من 186,461 إلى 179,961 بعد الحجز. تخضع RSU لخطط vesting قائمة على الخدمة، وعادةً ما تكون على مدى أربع سنوات مع تواريخ vesting ربع سنوية محددة في الملف.

هذا الملف هو تقارير عن جوائز الأسهم والاقتطاعات المرتبطة؛ فهو يوثق آليات المنح وجداول vesting ومستويات الملكية المستفيدة بعد الصفقة، ولكنه لا يقدم إجماليات التعويض بالدولارات بخلاف سعر الحجز أو مؤشرات مالية أخرى للشركة.

Patrick Harrison Carroll,Hims & Hers Health, Inc.(HIMS)的首席医疗官兼董事,已在 Form 4 上报告日期为 2025-09-15 的交易。他获授 16,521 RSU,按一对一转换为 A 类普通股,文件中还记载了额外的 RSU 授予,总计 16,521 + 8,148 + 4,840 + 3,533 单位。发行人出于税务代扣的需要,扣留了 6,500 股,按披露价格 $53.96,在扣留后A类普通股的受益所有权从 186,461 减少到 179,961。RSU 受基于服务的归属计划约束,通常为四年,文件中列出季度归属日期。该披露为股票奖励及相关代扣的报告;它记录授予机制、归属时间表和交易后受益所有权水平,但不提供扣留价格之外的以美元计的薪酬总额或公司其他财务指标。

Positive
  • RSU grants disclosed showing alignment of executive compensation with equity ownership
  • Detailed vesting schedules provided, specifying quarterly vesting over a four-year period
Negative
  • 6,500 shares withheld by the issuer to satisfy tax withholding, reducing direct beneficial ownership from 186,461 to 179,961
  • Form 4 contains no cash compensation totals or dollar-value aggregation of the awards beyond the withholding price

Insights

TL;DR: Routine RSU grants and tax-withholding reported; modest change in beneficial ownership, no cash proceeds or open-market sales disclosed.

The Form 4 documents service-based Restricted Stock Unit grants to an executive who is also a director, with vesting schedules over four years and quarterly vesting dates. The issuer withheld 6,500 shares to cover tax obligations at a stated price of $53.96, and the reporting persons reported direct Class A common stock decreased from 186,461 to 179,961 shares following withholding. The filing contains no information about exercise of options for cash, open-market dispositions, or additional compensation cash amounts.

TL;DR: Disclosure shows standard equity compensation mechanics and tax withholding; vesting schedules and insider status are clearly disclosed.

The reporting person is identified as both Chief Medical Officer and a director, and the Form 4 details multiple RSU grants with explicit service-based vesting schedules (4-year terms with quarterly vesting dates). The filing clearly states that RSUs convert one-for-one to Class A common stock and that shares were withheld for tax withholding. This is a routine insider disclosure consistent with equity-based compensation and Section 16 reporting requirements.

Patrick Harrison Carroll, Direttore Medico e amministratore di Hims & Hers Health, Inc. (HIMS), ha riportato operazioni datate 09/15/2025 sul Modulo 4. A lui sono stati conferiti 16.521 RSU che si trasformano one-for-one in azioni ordinarie di Classe A e ulteriori premi RSU elencati nel fascicolo per un totale di 16.521 + 8.148 + 4.840 + 3.533 unità tra le voci. L’emittente ha trattenuto 6.500 azioni per soddisfare la ritenuta fiscale a un prezzo riportato di 53,96 USD, riducendo la proprietà economica dichiarata di azioni ordinarie di Classe A da 186.461 a 179.961 dopo la trattenuta. Le RSU sono soggette a piani di vesting basati sul servizio, generalmente su quattro anni con date di vesting trimestrali indicate nel fascicolo.

Il fascicolo è una rendicontazione di premi azionari e ritenute correlate; documenta le meccaniche di concessione, i calendari di vesting e i livelli di proprietà economica post-trasazione, ma non fornisce totali di compenso in dollari oltre al prezzo di ritenuta o ad altri indicatori finanziari dell’azienda.

Patrick Harrison Carroll, Director Médico y director de Hims & Hers Health, Inc. (HIMS), reportó transacciones con fecha 15/09/2025 en el Formulario 4. Le otorgaron 16.521 RSU que se convierten uno a uno en acciones ordinarias Clase A y premios RSU adicionales listados en el expediente que suman un total de 16.521 + 8.148 + 4.840 + 3.533 unidades entre las entradas. El emisor retuvo 6.500 acciones para cumplir con la retención fiscal a un precio reportado de $53.96, reduciendo la propiedad beneficiaria reportada de acciones ordinarias Clase A de 186.461 a 179.961 tras la retención. Las RSU están sujetas a planes de vesting basados en el servicio, generalmente a lo largo de cuatro años con fechas de vesting trimestrales indicadas en el expediente.

El expediente es un informe de premios de acciones y retenciones relacionadas; documenta la mecánica de concesión, calendarios de vesting y niveles de propiedad beneficiosa post-trasacción, pero no proporciona totales de compensación en dólares más allá del precio de retención ni otros indicadores financieros de la empresa.

Patrick Harrison Carroll, Hims & Hers Health, Inc. (HIMS)의 최고의료책임자 겸 이사는 2025-09-15자로 Form 4에 거래를 보고했습니다. 그에게는 16,521 RSU가 부여되어 1대1로 Class A 보통주로 전환되며, 파일에 기재된 추가 RSU 보상도 합계 16,521 + 8,148 + 4,840 + 3,533 단위로 항목에 기재되어 있습니다. 발행사는 세금 원천징수를 충당하기 위해 6,500주를 보유했고, 보고된 가격 $53.96로 원천징수를 실시하여, 원천징수 후 Class A 보통주 유익소유가 186,461주에서 179,961주로 감소했습니다. RSU는 서비스 기반의 vesting 일정에 따라 일반적으로 4년 동안 분기별 vesting 날짜가 파일에 명시되어 있습니다.

이 제출물은 주식 보상 및 관련 원천징수에 대한 보고로, 부여 메커니즘, vesting 일정 및 거래 후 유익소유 수준을 문서화하지만, 원천징수 가격이나 회사의 다른 재무 지표를 넘어서는 보상 총액은 제공하지 않습니다.

Patrick Harrison Carroll, Directeur médical et administrateur de Hims & Hers Health, Inc. (HIMS), a signalé des transactions datées du 15/09/2025 sur le Formulaire 4. Il a reçu 16 521 RSU qui se convertissent en une action ordinaire de Classe A au même rapport et des suppléments RSU supplémentaires listés dans le dossier totalisant 16 521 + 8 148 + 4 840 + 3 533 unités. L’émetteur a retenu 6 500 actions pour satisfaire la retenue fiscale à un prix affiché de 53,96 USD, réduisant la propriété bénéficiaire déclarée d’actions ordinaires de Classe A de 186 461 à 179 961 après retenue. Les RSU sont soumises à des plans d’acquisition fondés sur le service, généralement sur quatre ans avec des dates d’acquisition trimestrielles indiquées dans le dossier.

Le dossier est un rapport sur les attributions d’actions et les retenues associées; il décrit les mécanismes d’attribution, les calendriers d’acquisition et les niveaux de propriété bénéficiaire post-transaction, mais ne fournit pas les totaux de rémunération en dollars au-delà du prix de retenue ni d’autres indicateurs financiers de l’entreprise.

Patrick Harrison Carroll, Chief Medical Officer und Direktor von Hims & Hers Health, Inc. (HIMS), berichtete Transaktionen vom 15.09.2025 im Formular 4. Ihm wurden 16.521 RSU gewährt, die eins-zu-eins in Class A Stammaktien umgewandelt werden, sowie zusätzliche RSU-Boni, die in der Einreichung aufgeführt sind und insgesamt 16.521 + 8.148 + 4.840 + 3.533 Einheiten ergeben. Der Emittent hielt 6.500 Aktien ein, um die Steuerabzüge zu decken, zu einem angegebenen Preis von 53,96 USD, wodurch die berichtete Beneficial Ownership der Class A Stammaktien nach dem Abzug von 186.461 auf 179.961 sinkt. Die RSUs unterliegen dienstbasierenden Vesting-Plänen, in der Regel über vier Jahre mit vierteljährlichen Vesting-Daten, die in der Einreichung angegeben sind.

Die Einreichung dokumentiert Equity Awards und damit verbundene Abzüge; sie beschreibt Vergabe-Mechanismen, Vesting-Zeitpläne und Post-Transaktions-Beneficial Ownership-Level, liefert jedoch keine Vergütungsbeträge in Dollar über den Abzugspreis oder andere Finanzkennzahlen des Unternehmens.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Carroll Patrick Harrison

(Last) (First) (Middle)
2269 CHESTNUT STREET, #523

(Street)
SAN FRANCISCO CA 94123

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 09/15/2025 M 16,521 A (1) 186,461 D
Class A Common Stock 09/15/2025 F 6,500(2) D $53.96 179,961 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 09/15/2025 M 8,148 (3) (3) Class A Common Stock 8,148 $0 40,744 D
Restricted Stock Unit (4) 09/15/2025 M 4,840 (5) (5) Class A Common Stock 4,840 $0 48,396 D
Restricted Stock Unit (4) 09/15/2025 M 3,533 (6) (6) Class A Common Stock 3,533 $0 49,463 D
Explanation of Responses:
1. The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU.
2. The shares of Class A Common Stock were withheld by the issuer to cover tax withholding obligations in connection with the reported vesting and settlement of RSUs.
3. The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with 25% of the RSUs vesting on December 15, 2023, and the remaining 75% of the RSUs vesting in substantially equal quarterly installments over the following 3 years, on the specified vesting dates of March 15, June 15, September 15 and December 15 (each, a "Company Quarterly Vesting Date") occurring thereafter.
4. The Restricted Stock Units ("RSUs") represent a contingent right to receive one share of Class A Common Stock for each RSU.
5. The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with the RSUs vesting in substantially equal quarterly installments on the specified vesting dates of March 15, June 15, September 15 and December 15 (each, a "Company Quarterly Vesting Date"), with the first such vesting date on June 15, 2024.
6. The RSUs are subject to a service-based vesting requirement, which shall be satisfied over a 4-year period, with the RSUs vesting in substantially equal quarterly installments on the specified vesting dates of March 15, June 15, September 15 and December 15 (each, a "Company Quarterly Vesting Date"), with the first such vesting date on June 15, 2025.
Remarks:
/s/ Kimberly Mather, Attorney-in-Fact for Patrick Harrison Carroll 09/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for HIMS?

The filing was made on behalf of Patrick Harrison Carroll, Chief Medical Officer and director of Hims & Hers Health, Inc.

What transactions were reported on the Form 4 dated 09/15/2025 for HIMS?

The Form 4 reports grants of RSUs (including 16,521 RSUs on 09/15/2025) and withholding of 6,500 Class A shares to cover tax obligations at $53.96 per share.

How did beneficial ownership change after the reported transactions?

Reported direct Class A common stock beneficial ownership decreased from 186,461 to 179,961 following the withholding.

What are the vesting terms for the RSUs disclosed?

The RSUs are subject to service-based vesting over a 4-year period with quarterly vesting dates (March 15, June 15, September 15, December 15) as specified in the filing.

Was any open-market sale or cash exercise reported?

No open-market sale or cash exercise of options is reported; only RSU grants and share withholding for tax are disclosed.
Hims & Hers Health Inc

NYSE:HIMS

HIMS Rankings

HIMS Latest News

HIMS Latest SEC Filings

HIMS Stock Data

12.40B
193.64M
10.63%
88.99%
33.02%
Household & Personal Products
Services-offices & Clinics of Doctors of Medicine
Link
United States
SAN FRANCISCO